Revolution Medicines

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on RAS and associated signaling pathways.

The company is utilizing their deep understanding of genetic drivers and adaptive resistance mechanisms in cancer, coupled with robust drug discovery and medicinal chemistry capabilities, to build a portfolio of compounds that inhibit critical signaling nodes within the RAS and associated pathways, such as the mTOR pathway. In doing so, they leverage their structure-based drug discovery capabilities to access unconventional sites on these challenging targets with differentiated approaches such as intra-molecular allosteric binding, tri-complex formation as a form of inter-molecular allostery, and bi-steric binding. Revolution Medicines’ cohesive approach of focusing on targets within these signaling pathways underpins their aspiration to domain expertise and a clinical strategy of exploring mechanism-based dosing paradigms and in-pathway combinations to optimize treatment.

The most advanced product candidate is RMC-4630, a clinical-stage drug candidate that potently and selectively inhibits SHP2, a central node in the RAS signaling pathway. In collaboration with their partner, Sanofi, Revolution Medicines is evaluating RMC-4630 in a multi-cohort Phase I/II clinical program for a range of tumor types featuring specific oncogenic mutations. Additionally, they are developing a portfolio of mutant-selective RAS inhibitors that could be the first potent, selective, cell-active inhibitors of the active, GTP-bound form of RAS, or RAS(ON). The pipeline also includes inhibitors of other frontier oncology targets within the RAS and mTOR pathways.